Objectives: Mycobacterium tuberculosis is a deadly human pathogen that causes the lung disease TB. M. tuberculosis latently infects a third of the world's population, resulting in 1.5 million deaths per year. Due to the difficulties and expense of carrying out animal drug trials using M. tuberculosis and rodents, infections of the zebrafish Danio rerio with Mycobacterium marinum have become a useful surrogate. However, the infection methods described to date require specialized equipment and a high level of operator expertise.
Introduction
Mycobacterium tuberculosis is a deadly human pathogen that latently infects a third of the world's population, resulting in 1.5 million deaths per year. 1 The emergence of MDR and totally drug resistant (TDR) isolates of M. tuberculosis has once again brought TB into the spotlight for all countries and has necessitated the development of novel drugs to combat this pathogen. 2, 3 Due to the difficulties and dangers involved in culturing M. tuberculosis, an airborne Biosafety Level 3 pathogen, fastergrowing and less pathogenic mycobacterial species, such as Mycobacterium smegmatis and Mycobacterium marinum, are routinely exploited for TB research and anti-mycobacterial drug discovery. 4 -7 M. marinum shares conserved virulence determinants with M. tuberculosis and is a pathogen of ectotherms (fish, amphibians and reptiles), as well as causing granulomatous skin infections in humans. 8, 9 Infection of the tropical zebrafish, Danio rerio, with M. marinum has been used to develop a surrogate in vivo model of TB pathogenesis, 10 which has proved useful for the rapid screening of potential anti-mycobacterial compounds. 11 However, microinjection is the most common route of infection of zebrafish larvae with M. marinum, a technique that requires specialized equipment and a high level of operator expertise. 11 Bioluminescence is a biological reaction that results in the production of light via a luciferase catalysed reaction. It is a naturally occurring process with several variants seen across several kingdoms and has been harnessed as a reporter for many different microbial species, including several mycobacteria 12, 13 in both in vitro and in vivo assays. 14, 15 Bioluminescence allows for non-invasive monitoring of luciferase-expressing bacteria within a host, as the light produced by the bacterium travels through the host tissues and can be readily detected. 15 -17 As tagged cells only produce a signal when alive, bioluminescence is an excellent reporter to assay rapidly for anti-mycobacterial compounds, non-destructively and in real-time, in microtitre plate formats using a luminometer, 15,18 -21 or in vivo using sensitive imaging equipment. 22 Zebrafish and other fish readily become naturally infected with M. marinum present in their environment. 23 However, it is not possible to tell which fish are infected at an early stage without euthanizing the animal and plating out for viable bacteria. 24 Here, we describe the use of bioluminescently tagged M. marinum M to establish natural infections in zebrafish larvae, utilizing the light emitted by these bacteria to identify which larvae have become infected. This allows us to select infected larvae for antimycobacterial drug screening, using bioluminescence to monitor how effective test treatments are in a non-destructive manner.
Materials and methods

Bacterial strains and plasmids
Bacterial strains and plasmids used throughout this study are described in Table 1 . Bacteria were transformed as previously described. 25 M. marinum strains were grown at 288C and M. tuberculosis at 378C, with shaking at 200 and 100 rpm, respectively, in Middlebrook 7H9 broth (Fort Richard) supplemented with 10% ADC enrichment medium (Fort Richard) and 0.5% glycerol (Sigma-Aldrich) under the appropriate antibiotic selection [kanamycin at 25 mg/mL and hygromycin at 50 mg/mL (Sigma-Aldrich)].
In vitro drug testing M. marinum BSG101 and M. tuberculosis BSG001 were grown without antibiotic selection to mid-log phase, then diluted to an OD 600 of 0.01. Bacteria were aliquoted (100 mL, 5×10 5 cfu/mL) into the wells of a black 96-well microtitre plate (Grenier Bio-One). Test compounds were dissolved in DMSO, added 1:100 to the top most well and then diluted 2-fold in a series down the plate. The plates were incubated at 288C (M. marinum) or 378C (M. tuberculosis) and bioluminescence monitored daily over 7 days using a Victor X1 luminometer (PerkinElmer).
Fish husbandry
Standard husbandry conditions approved by the University of Auckland Animal Ethics Committee (approval number R001343) were used to maintain adult zebrafish (D. rerio). Under the age of 30 days, zebrafish are classed as larvae. Experiments that use larvae are exempt from the requirement for approval from an animal ethics committee, according to Section 2, d(ii) of the New Zealand Animal Welfare Act 1999.
Larvae were obtained from natural spawnings and raised at 288C in E3 Medium (44 mg/L calcium chloride, 81 mg/L magnesium sulphate, 12 mg/L potassium chloride and 292 mg/L sodium chloride). The medium was supplemented with 0.003% phenylthiourea to inhibit pigmentation when larvae were being imaged.
Natural infection of zebrafish larvae
M. marinum strains were grown to mid-log phase (OD 600 between 0.8 and 2) without antibiotic selection, washed once in E3 before being adjusted to an OD 600 of 1. The approximate concentration should be 5×10 8 cfu/mL; this was confirmed by retrospectively plating inocula on to 7H11 with 10% OADC medium supplement and 0.5% glycerol. Zebrafish larvae at 2 days post-fertilization were dechorionated, either manually or using pronase, as previously described. 26 Groups of larvae (50 -300) were then placed in 90 mm Petri dishes containing 25 mL of E3 supplemented with varying concentrations of M. marinum (by varying the volume of adjusted bacteria) and incubated for 4 days at 288C. After infection, any non-internalized bacteria were removed by gently washing larvae four times with fresh E3 in groups of 10 in separate wells of a 24-well tissue culture plate (BD Falcon) using gentle aspiration of the medium. Larvae were left in the 24-well plate overnight to remove transient bacteria and then rinsed four times in E3 to remove the transient population. Larvae were then individually placed into the wells of a clear-bottomed black 96-well microtitre plate (Nunc) with 100 mL of E3 and prepared for drug treatment.
Injection of zebrafish larvae
M. marinum strains were prepared as above. Zebrafish larvae 2 days post-fertilization were manually dechorionated, anaesthetized using 0.168 mg/mL tricaine (Sigma -Aldrich) in E3 medium 27 and infected by microinjection into the caudal vein as previously described. 
Measurement of bioluminescence from zebrafish larvae
All bioluminescent measurements were carried out using a Victor X1 luminometer (PerkinElmer) with a 1 s exposure time on an open filter.
Bioluminescence from zebrafish infected with M. marinum BSG100 was visualized after addition of luciferin (30 mg/mL) (Gold Biotechnology).
Drug testing in zebrafish larvae
Bioluminescence from infected zebrafish larvae was measured on a luminometer after removal of transient bacteria and detectably infected larvae [relative light units (RLUs) .20] were randomly distributed within drug treatment groups. Drugs were made up to 100× working concentration in an appropriate solvent. They were diluted 1:10 in E3 and 10 mL of diluted drug was placed into each well of the 96-well plate containing 100 mL of E3. The final concentration of the test compounds was 10 mM. E3 was used as a no treatment control. Larvae were treated at 5 days postinfection and incubated at 288C during treatment.
Microscopy
For imaging on the fluorescent inverted microscope, larvae were anaesthetized in tricaine as above and mounted in 3% (w/v) methylcellulose in E3 to reduce larvae movement. Images were captured on a Nikon SMZ1500 microscope with NIS-Elements F version 4.00.06 software.
Statistics
Data analysis was performed using the GraphPadPrism (version 5) package. For box-whisker plots ranges and medians are shown for each dataset. The edges of the boxes represent the 25th and 75th quartiles, the internal horizontal line represents the median and the whiskers represent the minimum and maximum values. To determine P values first a D'Agostino and Pearson normality test was conducted. For data that were determined to be normally distributed, treatment groups were compared using ANOVA with Bonferroni's post hoc analysis. For those that were not normally distributed groups were compared using the Kruskal-Wallis test with Dunn's post hoc analysis. For larvae infected by caudal vein injection, survival data were analysed using the log-rank (Mantel-Cox) test.
Results
Luminescence can be used to monitor zebrafish larvae naturally infected with luciferase-tagged M. marinum
Bioluminescence from infected larvae rose above background levels from 4 days post-infection, with comparable levels of light emitted from M. marinum tagged either with a modified firefly luciferase (BSG100) or with a modified bacterial luciferase (BSG101) (Figure 1 ). Natural infection of larvae with M. marinum did not result in any premature deaths when compared with uninfected larvae. Larvae infected with M. marinum labelled with the firefly luciferase produced more light [median maximum value of 709 RLUs (ranging from 328 to 2872)] compared with the bacterial-luciferasetagged strain [median maximum value of 446 RLUs (ranging from 122 to 796)] (Figure 1) . However, the exogenous addition of luciferin increased the time required to carry out the assay, and the expense of the technique, so we selected bacterial-luciferasetagged M. marinum M (BSG101) for further study.
Natural infection results in gill colonization and transient gut colonization
We investigated the nature and location of natural M. marinum infection of larvae using a strain of M. marinum expressing the red fluorescent protein tdTomato 11 (BSG102) (Figure 2 ). We observed fluorescently tagged bacteria throughout the digestive tract, clustering around the developing gills and lower jaw of the larvae (Figure 2a and b) . Bacteria in the digestive tract were seen to be removed following defecation, suggesting transient colonization. After washing infected larvae in fresh medium and incubating for a further 24 h, we observed that the bacteria that were previously present within the digestive tract had gone, while the bacteria associated with the developing gills were still present (Figure 2c ). We observed that the digestive tract remained clear of detectable bacteria for the majority of the experiment, with some non-transient colonization appearing 11 days postinfection (data not shown).
Optimization of infectious dose and infection protocol
To determine the minimum dose for establishing a traceable infection, we incubated larvae with concentrations of M. marinum BSG101 ranging from 1×10 4 to 1×10 7 cfu/mL and followed bioluminescence over 12 days using a luminometer. A dose of 1×10 7 cfu/mL established an infection that we could reliably detect above background levels ( Figure S1 , available as Supplementary data at JAC Online). This dose resulted in 40%-60% of the exposed larvae becoming detectably bioluminescent, depending on the experiment (data not shown). When larvae were exposed to a dual bioluminescent/fluorescent-tagged strain of M. marinum (BSG103) and examined by fluorescence microscopy, we observed that .90% of the larvae were infected, but only half of these could be detected by luminometry (data not shown). In an effort to reduce the time required to process larvae for infection, we investigated the effect of manual dechorionation versus chemical Natural mycobacterial infection of zebrafish larvae JAC treatment with pronase. We observed that pronase treatment reduced the proportion of infected larvae detectable by luminometry (45% for manual, 7% for pronase) and light levels from infected larvae were also consistently lower RLUs for manual, 20-76 RLUs for pronase).
For these reasons, we adopted the following optimized protocol for further experiments: (i) manual dechorionation of larvae 2 days post-fertilization; (ii) immersion in medium containing 1×10 7 cfu/mL M. marinum for 4 days at 288C; (iii) wash in fresh medium and incubation for a further 24 h at 288C; and (iv) transfer of individual larvae to the wells of a black 96-well plate using a sterile plastic Pasteur pipette for measurement of light and drug intervention studies.
Drug treatment of naturally infected zebrafish larvae
Zebrafish larvae, infected using the optimized natural infection protocol, were treated with rifampicin and a variety of nitroimidazole-based next-generation and experimental antimycobacterial drugs (Table S1 and Figure 3 ). For comparison, we treated larvae infected through caudal vein microinjection with a subset of the compounds (Figure S2 ), as well as M. marinum and M. tuberculosis grown in laboratory medium (Figure 3 ). The data are summarized in Table 2 . We considered all injected larvae as infected, whereas we only selected larvae with observable light emission after natural infection for use in drug intervention studies. For naturally infected larvae we used reduction in light emission as a surrogate measure of anti-mycobacterial activity; for injected larvae, we measured drug efficacy by larval survival.
We observed that at the concentration used, five of the six treatments tested (pretomanid, delamanid, SN30488, SN30527 and rifampicin) significantly reduced the bioluminescent signal from naturally infected zebrafish larvae (P, 0.001, KruskalWallis test with Dunn's multiple comparisons) (Figure 3b) . Similarly, we observed a 90% survival rate for BSG101 injected larvae treated with pretomanid and delamanid, compared with 20% survival of untreated injected larvae or those treated with SN30982 or rifampicin. These same treatments retarded the growth of M. tuberculosis BSG001 in vitro (Figure 3c ). In contrast, only three of the six treatments tested (delamanid, SN30527 and rifampicin) retarded the growth of M. marinum BSG101 in vitro (as shown by a lack of increase in bioluminescence) (Figure 3a) .
Discussion
There is a clear and desperate need for new medicines to treat TB. Due to the infectious nature of M. tuberculosis, non-tuberculous mycobacteria such as M. marinum are widely used as surrogates. 4, 6, 29, 30 A major drawback of using M. marinum for antimycobacterial compound screening is that the in vitro resistance profile of the bacterium is very different from M. tuberculosis. This difference can be observed in the drastically different MIC values of the compounds tested for the two organisms in this study ( Table 2) . Two of the compounds (pretomanid and SN30488) were not effective against in vitro-grown M. marinum but were effective against M. tuberculosis. This means that screening compounds for activity against M. marinum in vitro runs the risk of missing potential anti-TB agents.
Infection of zebrafish, either as adults or as larvae, by injection with M. marinum has proved to be a useful model for studying mycobacterial pathogenicity and for drug screening. 11, 31, 32 However, current infection protocols require specialized equipment and a high level of operator expertise. We have shown that zebrafish larvae can be infected by exposure to M. marinum in the medium, and that infection dynamics can be monitored 33 It is unsurprising that the larvae could be infected via bathing, as this should represent one of the ways that zebrafish could become naturally infected in the wild. However, without the use of bioluminescence to visualize M. marinum, the easy identification of infected larvae would not be possible.
We observed that the proportion of larvae that became infected varied depending on the housing conditions. Initially larvae were housed in groups of 50 for infection but this resulted in a low proportion of measurable infections. When we increased the number to 300, the proportion of larvae with a measurable infection rose to 40%. We speculate that this is due to the increased motion of the fish in the medium allowing for greater mixing. Another possibility is that M. marinum may phenotypically change as it travels through the larval gut, making it more infectious. Such hyperinfectivity has been reported for Vibrio cholera and Citrobacter rodentium.
-36
As several bioluminescent reporter systems exist, we wanted to establish which one would give the best results for this assay. We compared mycobacterial optimized bacterial luciferase (lux) and the codon-optimized red shifted firefly luciferase (RTluc). 12 The bacterial lux construct contains all the required genes to make both the substrate and the catalytic enzyme to produce light. In the case of the firefly luciferase, the substrate has to be added exogenously. While M. marinum tagged with the firefly luciferase did produce higher levels of light, this was not enough to compensate for the increased cost to the assay, both in terms of expense and time as a result of having to add the exogenous substrate. We chose to use M. marinum tagged with bacterial lux throughout to produce as streamlined and economic an assay as possible. We also investigated whether the assay could be accelerated by using pronase treatment to dechorionate larvae. While pronase treatment did reduce the time required to prepare larvae, more bacteria were needed to establish an infection compared with the dose needed to infect manually dechorionated larvae. Similarly, the proportion of infected larvae with visible bioluminescence was also reduced. One possible explanation for this difference could be that pronase treatment may result in an increased inflammatory reaction within the larvae, resulting in greater initial killing of the bacteria.
The optimized natural infection assay protocol we have established requires manual dechorionation of zebrafish larvae 2 days post-fertilization, followed by bathing with 1×10 7 cfu/mL Natural mycobacterial infection of zebrafish larvae JAC M. marinum for 4 days. Larvae are then removed from the infected medium, washed and placed in fresh medium and kept overnight to allow for the clearance of transiently colonizing bacteria. After a further wash, larvae can be housed within individual wells of a clear bottom, black 96-well plate for measurement of infection dynamics using bioluminescence. We investigated whether the optimized natural infection assay could be applied to the testing of anti-mycobacterial compounds, using rifampicin and a variety of nitroimidazole-based nextgeneration and experimental anti-mycobacterial drugs (Table S1 ). Delamanid was recently approved for clinical use, while pretomanid is in human Phase III combination trials. 37 The experimental compounds SN30488, SN30527 and SN30982 38 are analogues of pretomanid, with varying lipophilic side chains, selected for their wide range of potencies against M. tuberculosis cultures. Five of the six compounds we tested reduced the luminescence from infected larvae to below background levels. Importantly, these same five treatments also retarded the growth of M. tuberculosis in vitro.
Overall this study has demonstrated that it is possible to carry out high-throughput in vivo drug screening in the zebrafish model using larvae naturally infected with bioluminescent M. marinum M. Natural infection is quicker than injection and requires less expertise. Larvae can be screened in 96-well plates and drug efficacy rapidly identified over the course of 10 days. Through the use of a luminometer with a plate stacker this process can be semiautomated to reduce the hands on time. While this is moderately slower than previously reported automated robotic systems, it is also a fraction of the cost. The result is an assay that can be carried out by a wide variety of laboratories for minimal cost and without high levels of zebrafish expertise. Widening participation in TB research and pre-clinical drug discovery in this way should accelerate the progress towards new and better treatments for TB and other neglected mycobacterial infections. Dalton et al.
